New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
T-cell redirecting bispecific antibodies in multiple myeloma: optimal dosing-schedule and duration of treatment.
À¶Ý®ÊÓƵ
T-cell redirecting bispecific antibodies in multiple myeloma: optimal dosing-schedule and duration of treatment. Blood cancer discovery van de Donk, N. W., Rasche, L., Sidana, S., Zweegman, S., Garfall, A. L. 2024Abstract
T-cell redirecting bispecific antibodies (BsAbs) induce significant responses in heavily pretreated MM. BsAbs are currently administered in a dose-dense fashion until disease progression. However, continuous therapy is associated with safety concerns, including a high risk of infections, and high costs. In addition, chronic exposure to BsAbs, and thus long-term T-cell stimulation, induces T-cell exhaustion, which may contribute to relapse. There is increasing evidence that the strategy of induction treatment followed by maintenance with longer intervals between BsAb doses, or limited treatment duration with cessation of therapy in patients who achieve deep remission, improves the balance between toxicity and efficacy.
View details for
View details for